# Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Source: https://onco.cc/trials/nct05797168/  
OnCo record `nct05797168` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT05797168 as recruiting, last updated 2026-10-05. Enrolment is 622 planned participants, an estimate. Interventions: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab. Primary measures include Number of participants with adverse events/serious adverse events; The number of participants with dose limiting toxicity(DLT), as defined in the protocol. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: FONTANA
- Tags: ctgov-ingest
- Registry id: NCT05797168
- Phase: 1/2
- Setting: A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT05797168: https://clinicaltrials.gov/study/NCT05797168

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [AZD5335](https://onco.cc/drugs/azd5335/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Palacaparib](https://onco.cc/drugs/palacaparib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05797168.json